muscles

A C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Sarcopenia is a manifestation of musculoskeletal aging, yet no approved therapy is available. A major challenge is not the lack of potential interventions, but the difficulty of efficiently identifying which candidates should advance to aged-mammal validation. Sarcopenia is driven by...

🗓️ 2026-07-28
📰 Publication: Aging And Disease
Read MoreA C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

Cancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO,...

🗓️ 2026-07-28
📰 Publication: Cell Reports Medicine
Read MoreTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

YAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

Sarcopenia, an age-related degenerative disease of skeletal muscle, is closely associated with osteoporosis and other bone disorders, partly due to dysregulated endocrine function of skeletal muscle. However, the specific cellular sources and molecular mechanisms driving this pathological secretory phenotype remain...

🗓️ 2026-07-27
Read MoreYAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

CXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

BACKGROUND

Sarcopenia is a progressive muscle-wasting condition driven in part by chronic inflammation; however, the specific inflammatory mediators that contribute to functional decline in humans and their responses to exercise remain poorly defined.

METHODS

We analyzed public ribonucleic acid (RNA) datasets to identify...

🗓️ 2026-07-23
📰 Publication: Journal Of Sport And Health Science
Read MoreCXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

Selective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

BACKGROUND

Skeletal muscle atrophy is a frequent comorbidity of metabolic disorders and chronic diseases, and despite its high prevalence, no pharmacological therapy is available, representing a major unmet clinical need. Adiponectin and its receptors are key regulators of skeletal muscle metabolism,...

🗓️ 2026-07-22
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSelective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

Biological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

INTRODUCTION

Sarcopenia, the accelerated loss of muscle mass, strength and function with age, is associated with adverse health outcomes. DNA methylation accumulates across life and methylation clocks (which provide a measure of biological age) could potentially be used to predict individuals...

🗓️ 2026-07-19
📰 Publication: Aging Clinical And Experimental Research
Read MoreBiological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

Association between GDF-15 and sarcopenia progression in older adults: results from a population-based study.

BACKGROUND

Growth differentiation factor-15 (GDF-15), a stress-induced cytokine, has been implicated in pathways related to muscle degeneration, although findings regarding its association with sarcopenia remain heterogeneous. This study investigated the association between serum levels of GDF-15 and sarcopenia progression in community-dwelling...

🗓️ 2026-07-18
📰 Publication: Ebiomedicine
Read MoreAssociation between GDF-15 and sarcopenia progression in older adults: results from a population-based study.

Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Cancer cachexia significantly impacts the quality of life of cancer patients, predicting therapy response and survival. Cachexia prevalence and severity increases over the course of disease progression, affecting up to 80% of patients with metastatic cancer. Despite this, cachexia is...

🗓️ 2026-07-18
📰 Publication: Cancer And Metastasis Reviews
Read MoreUnderstanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Pre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

PURPOSE

Cancer cachexia is a life-threatening complication of advanced malignancies, driven by profound systemic metabolic reprogramming and anorexia. Insulin action is markedly impaired in patients with cancer and may contribute directly to cachexia pathogenesis. However, the interplay between weight loss, food...

🗓️ 2026-07-18
📰 Publication: Molecular Metabolism
Read MorePre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

Sex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Cancer cachexia is characterised by progressive skeletal muscle wasting and dysfunction, yet the early events that precede overt muscle wasting remain poorly defined. Here, we utilised a time-coursed C26 carcinoma model in male and female mice to define the pre-cachectic...

🗓️ 2026-07-17
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreSex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Sarcopenia Predicts Postoperative Cognitive Impairment and Poor Surgical Outcomes in Older Adults: A Prospective Cohort Study.

BACKGROUND

Sarcopenia is a progressive skeletal muscle disorder prevalent in older adults, yet its role as a risk factor for acute postoperative cognitive decline-an early manifestation within the spectrum of perioperative neurocognitive disorders (PND)-remains underexplored. We hypothesize that preoperative sarcopenia increases...

🗓️ 2026-07-16
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia Predicts Postoperative Cognitive Impairment and Poor Surgical Outcomes in Older Adults: A Prospective Cohort Study.

Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.

BACKGROUND/PURPOSE OF THE STUDY

The Asian Working Group for Sarcopenia (AWGS) updated its criteria in 2025, adding a body mass index (BMI)-adjusted muscle index (ASM/BMI) to the conventional skeletal muscle index (SMI). We aimed to compare the prognostic performances of the...

🗓️ 2026-07-15
📰 Publication: Hepatology International
Read MorePrognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.

Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

BACKGROUND

Highly effective anti-obesity medications (AOMs) induce substantial weight loss and have renewed debate on appropriate treatment targets. Weight loss comprises reductions in fat mass (FM) and fat-free mass (FFM), with skeletal muscle (SM) as the major component of FFM. Clinical...

🗓️ 2026-07-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDefining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.

Cancer cachexia is a wasting condition characterized by muscle loss and reduced quality of life in cancer patients. Although biological sex differences in the progression of cancer cachexia have been increasingly recognized, their role during chemotherapy-treated cancer cachexia remains largely...

🗓️ 2026-07-15
📰 Publication: American Journal Of Physiology-Endocrinology And Metabolism
Read MoreDifferential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a pre-clinical model of colorectal cancer by biological sex.

Calcium Beta-Hydroxy-Beta-Methylbutyrate-Enriched Nutritional Supplementation During Dietary Weight Loss in Adults With Obesity: A Randomized Controlled Trial.

BACKGROUND

Dietary and pharmacologic weight loss can reduce skeletal muscle. Whether calcium beta-hydroxy-beta-methylbutyrate (CaHMB)-enriched supplementation preserves muscle while promoting fat loss in adults with obesity remains uncertain. We evaluated a CaHMB-enriched nutritional supplement during energy restriction.

METHODS

In this randomized, double-blind, controlled trial,...

🗓️ 2026-07-14
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCalcium Beta-Hydroxy-Beta-Methylbutyrate-Enriched Nutritional Supplementation During Dietary Weight Loss in Adults With Obesity: A Randomized Controlled Trial.

Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank.

OBJECTIVE

To examine whether sarcopenic obesity (SO) is associated with incident type 2 diabetes (T2D) beyond obesity or sarcopenia alone and whether associations differ by sex, age, and transitions in body composition phenotypes over time.

RESEARCH DESIGN AND METHODS

We studied 479,607 diabetes-free...

🗓️ 2026-07-13
📰 Publication: Diabetes Care
Read MoreSarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!